Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Table 3 Treatment-related adverse events in the two groups, n (%)
| Adverse events | Control group (n = 92) | Experimental group (n = 31) | P value |
| Myelosuppression | 49 (53.26) | 18 (58.06) | 0.798 |
| Nausea | 27 (29.35) | 13 (41.94) | 0.284 |
| Diarrhea | 18 (19.57) | 7 (22.58) | 0.918 |
| Fatigue | 18 (19.57) | 6 (19.35) | 1.000 |
| Proteinuria | 16 (17.39) | 3 (9.68) | 0.397 |
| Hypertension | 7 (7.61) | 5 (16.13) | 0.302 |
| Hepatic dysfunction | 24 (26.09) | 10 (32.26) | 0.666 |
| Thyroid dysfunction | 13 (14.13) | 7 (22.58) | 0.411 |
| Hand-foot syndrome | 8 (8.70) | 2 (6.45) | 1.000 |
| rCCEP | 0 (0.00) | 16 (51.61) | < 0.001 |
- Citation: Zhang C, Wu SH, Jin L, Lu L, Li J, Jin S. Propensity score-based real-world study of immune checkpoint inhibitor combination therapy in microsatellite stable/proficient mismatch repair metastatic colorectal cancer. World J Gastrointest Oncol 2026; 18(11): 124022
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/124022.htm
- DOI: https://dx.doi.org/10.4251/wjgo.124022